The purpose of this research is to examine how the immune system in the nose (nasal mucosa) responds after children receive the nasal spray influenza vaccine. The study will involve children receiving two doses of the nasal spray vaccine and collecting samples from the nasal lining to measure the presence of vaccine viruses and immune responses. Small absorptive devices will be used to collect fluid from inside the nose at various timepoints after vaccination.

Researchers will analyze these samples to understand how the immune system in the nose reacts to the vaccine, including the production of protective antibodies (proteins that help fight infection). They will also monitor for any respiratory symptoms through questionnaires completed by parents. Blood samples may be collected from some participants, though this is optional.

Participants in the study will receive the vaccines as injections. The VaxigripTetra vaccine is administered either into the muscle or under the skin, while the Zoonotic Influenza Vaccine Seqirus is given directly into the muscle. The study will monitor the immune response by measuring the levels of antibodies and specific immune cells in the blood. This will help determine how well the vaccines work in stimulating the body’s defense mechanisms against the influenza viruses.

The study will take place over a period of time, with participants receiving doses of the vaccines and then having their immune responses checked at various intervals. The main focus is on the body’s production of antibodies and the activation of immune cells that can fight off the influenza viruses. This research aims to provide valuable insights into the effectiveness of these vaccines in preventing influenza infections.

The purpose of the study is to evaluate how effective and safe the CR9114 treatment is when given to healthy adults who are exposed to the flu virus. Participants will receive either the CR9114 treatment, a placebo, or the flu virus through a nasal spray. The study will monitor participants for a short period to observe any changes in flu symptoms and to ensure the treatment is safe.

Throughout the study, participants will be closely observed to track the occurrence and severity of any flu symptoms. The study aims to determine if the CR9114 treatment can reduce the incidence of flu symptoms and how well participants tolerate the treatment. This research is important for developing new ways to prevent and treat the flu in the future.

Participants will receive one injection of the vaccine into a muscle. Blood samples will be taken before the vaccination and again 14 days after the vaccination to measure the level of antibodies, which are proteins that help fight off infections. The study will check how many people reach a protective level of antibodies and how many people have a significant increase in antibody levels after vaccination. The vaccine contains inactive flu virus particles that cannot cause the flu but help the body build protection against it.

During the study, any side effects will be recorded, including reactions at the injection site such as pain or redness, and general symptoms like fever or tiredness that may occur in the week after vaccination. Any serious health problems or unexpected reactions will also be monitored throughout the entire study period. The study will compare the vaccine response between different groups including people with obesity, people with obesity and diabetes, people with normal weight, and pregnant women with and without obesity.

Participants in this study will be randomly assigned to one of three groups. One group will receive TETRALITE with a lower dose of adjuvant, another group will receive TETRALITE with a higher dose of adjuvant, and the third group will receive Vaxigrip Tetra without adjuvant. Each person will receive only one injection during the study. The study is observer-blind, which means that the participants and some of the study staff will not know which vaccine is being given, but this information will be known to others involved in conducting the study.

After receiving the vaccine, participants will be monitored for any reactions or side effects. For the first seven days, specific reactions at the injection site and general symptoms throughout the body will be recorded. Any other health problems will be tracked for 28 days after vaccination. Serious health problems, potential immune-related disorders, and other specific health events will be monitored for 180 days. Blood samples will be taken before vaccination and at several time points afterward, including at 7 days, 28 days, and 180 days, to measure the body’s immune response to the vaccine and to check for any changes in blood test results.

The study involves several different vaccine formulations that will be given as a single intramuscular injection. Some participants will receive the experimental mRNA vaccines, while others will receive traditional inactivated influenza vaccines for comparison. Each participant will receive one 0.5 milliliter dose of the assigned vaccine.

After vaccination, participants will be monitored for immune response through blood tests and for any side effects for up to 6 months. The study will track both expected injection site reactions and any unexpected health events. Participants will need to record their symptoms in an electronic diary and attend several follow-up visits to the study site for health checks and blood samples.

The study will test several different formulations of the vaccine, including versions containing various influenza virus strains. Some participants will receive the experimental mRNA vaccine candidates, while others will receive currently available flu vaccines for comparison. The study will monitor how well the immune system responds to the vaccines and track their safety.

Participants will receive a single dose of 0.5 milliliters of vaccine and will be monitored for 6 months afterward. During this time, researchers will check for immune responses through blood tests and record any side effects that occur. The study will look at both expected injection site reactions and any unexpected health events that might happen after vaccination.

The purpose of the study is to understand how these vaccines help the body build immunity, particularly in the airways, which are the passages that carry air to the lungs. Participants in the study will receive either the nasal spray or the injectable vaccine, and some may receive a placebo, which looks like the real vaccine but does not contain any active ingredients. The study will monitor participants over a period of time to see how their immune systems respond to the vaccines.

Throughout the study, researchers will collect samples to measure the body’s immune response. This includes looking at specific cells and antibodies, which are proteins that help fight infections. The study aims to provide insights into how well each vaccine works in establishing immunity against different strains of the flu virus. This information could help improve flu prevention strategies in the future.

The purpose of the study is to evaluate how well these vaccines work in producing an immune response and how safe they are for the participants. The study will involve receiving one of the vaccines through an injection. Participants will be monitored for their immune response to the vaccine strains, which are specific types of the flu virus, and for any side effects. The study will last for about a year, with the main focus on the immune response measured at 29 days after vaccination.

Participants will include healthy individuals or those with stable health conditions that increase their risk of complications from the flu. The study aims to ensure that the high-dose vaccine is as effective and safe as the other vaccines. The vaccines are administered using a pre-filled syringe, which is a single-use device. The study will help determine the best vaccine option for older adults to protect them against the flu.

The study involves comparing the effects of the vaccine when used as either a booster shot in people who have already received OVX836 before, or as a first-time vaccination in those who haven’t. Participants will receive a single injection of either 180 or 480 micrograms of the vaccine solution. The study is designed as a double-blind trial, which means neither the participants nor the researchers directly involved in giving the vaccine know who receives which dose.

During the study, researchers will monitor participants’ immune system responses to the vaccine and track any side effects that may occur. This includes checking for both expected reactions at the injection site and throughout the body, as well as any unexpected health issues. The study will also track whether participants develop any respiratory infections, including influenza, during the study period.

The main goal of the study is to see how the timing of the vaccine affects the body’s immune response, specifically the level of antibodies, which are proteins that help fight infections. Participants will receive the vaccine at different times of the day, and their antibody levels will be measured 28 days after vaccination. The study will also look at other factors, such as the participants’ natural sleep-wake patterns, known as chronotype, and the occurrence of flu-like symptoms over a six-month period.

Participants will be randomly assigned a time to receive their vaccine and will be monitored for changes in their immune response. The study aims to provide insights into whether the time of day can influence the effectiveness of the flu vaccine, potentially leading to improved vaccination strategies for older adults. The study is expected to conclude by May 2025.

The purpose of the study is to evaluate how effective the high-dose vaccine is compared to the standard-dose vaccine in reducing the risk of hospitalization due to influenza or pneumonia. Pneumonia is a lung infection that can be a serious complication of influenza, especially in older adults. Participants in the study will receive either the high-dose or standard-dose vaccine through an intramuscular injection, which means the vaccine is given as a shot into a muscle.

Throughout the study, researchers will monitor participants to see if they are hospitalized for influenza, pneumonia, or any other cardio-respiratory diseases, which affect the heart and lungs. They will also track all-cause hospitalizations and mortality. The study aims to provide valuable information on which vaccine might offer better protection for older adults, ultimately helping to guide future vaccination strategies for this age group.

The purpose of the study is to evaluate how effective the high-dose vaccine is compared to the standard-dose vaccine in reducing the risk of hospitalization due to flu or pneumonia in the specified age group. Participants in the study will receive one of the two vaccines through an injection into the muscle. The study will monitor the health of participants to see if there is a difference in the number of hospitalizations for flu or pneumonia between the two groups.

Throughout the study, researchers will also look at other health outcomes, such as hospitalizations for any heart or lung-related diseases, overall hospitalizations, and overall mortality. The study aims to provide valuable information on which vaccine might offer better protection for older adults against serious flu-related complications.

Participants in the study will receive either the BIMERVAX vaccine, the Fluad Tetra vaccine, both vaccines together, or a placebo, which is a substance with no active ingredients. The vaccines are administered through an injection into the muscle. The study will monitor participants for any reactions or side effects for a period of time after the vaccination. This includes checking for any local reactions at the injection site, as well as any general reactions throughout the body.

The trial will also measure the levels of antibodies, which are proteins made by the immune system to fight infections, in the participants’ blood. This will help determine how well the vaccines work when given together. The study aims to provide valuable information on the safety and effectiveness of coadministering these vaccines in older adults, which could help guide future vaccination strategies.

The purpose of this study is to compare how well the MF59-adjuvanted influenza vaccine works in preventing the flu compared to a non-adjuvanted vaccine in adults aged 65 and older. An adjuvant is a substance added to a vaccine to help boost the body’s immune response to the vaccine. Participants in the study will receive one of the two vaccines and will be monitored to see if they develop the flu, confirmed by a test called RT-PCR, which detects the presence of the virus in the body.

The study will take place over the course of the flu season, starting 14 days after vaccination. Participants will be observed for any side effects and the occurrence of flu symptoms. The study aims to provide valuable information on the safety and effectiveness of these vaccines in older adults, helping to improve flu prevention strategies for this age group.

The purpose of the study is to find and confirm the appropriate dose of the vaccine and to assess its safety and how well it triggers an immune response. Participants will receive the vaccine through an injection into the muscle. Some participants may receive a placebo, which is a substance with no active ingredients, to compare the effects. The study will monitor participants for any side effects and measure their immune response over several months.

Throughout the study, participants will be asked to attend follow-up visits to check their health and collect data on their immune response. The study aims to ensure that the vaccine is safe and effective in preventing influenza infection in healthy individuals. This research is important for developing better flu vaccines that can protect more people from getting sick during flu season.

Participants in the study will receive a single dose of the OVX836 vaccine through an injection. The study will monitor the occurrence of flu symptoms and any side effects after vaccination. The goal is to determine if the vaccine can effectively prevent the flu and to assess its safety. The study will also look at the body’s immune response to the vaccine, which involves measuring specific immune cells and antibodies that help fight the flu virus.

The trial will take place over a period of time, with participants being observed for any flu symptoms or side effects. The study will also evaluate the severity and duration of any flu-like symptoms that occur. By comparing the results between those who receive the OVX836 vaccine and those who receive a placebo, researchers aim to gather important information about the vaccine’s potential to protect against the flu.

The purpose of the study is to assess how safe and tolerable a single dose of EV25 is when given through the nose. Participants will receive either the EV25 nasal spray or a placebo. The study will also look at how much of the drug is present in the body over time and its effects on the body, especially in those who have been exposed to the Influenza A Virus. The study will be conducted in two parts: the first part involves healthy participants, and the second part involves participants who are exposed to the virus.

Participants will be monitored for any side effects and changes in their health through various assessments, including laboratory tests and physical examinations. The study aims to gather information on the safety and potential benefits of EV25 in preventing or reducing the effects of the Influenza A Virus. This research is important for developing new treatments that could help manage or prevent flu infections in the future.

The purpose of the study is to assess the presence and level of antibodies, which are proteins in the blood that fight infections, against the circulating influenza virus strains and the vaccine strains of the current season. Participants will receive the vaccine through an injection into the muscle. Blood samples will be taken before and after vaccination to measure the immune response. The study will also look at cellular immunity, which involves the body’s cells responding to the virus, and will measure substances like cytokines, which are proteins that help control the immune response.

The study will take place over several years, with the goal of understanding how well the vaccine works in healthcare workers who are regularly exposed to the flu. This information could help improve future flu vaccines and protect people from getting sick. Participants will be monitored throughout the study to ensure their safety and to gather important data on how their bodies respond to the vaccine.

During the study, participants will receive either the new mRNA-1010 vaccine or a standard licensed influenza vaccine called Influsplit Tetra through an intramuscular injection. Both vaccines are designed to protect against different strains of influenza viruses. The study will monitor participants for any side effects and track how well the vaccines prevent flu-like illness caused by influenza viruses.

The research team will collect information about vaccine reactions in the first week after vaccination, track any unexpected health issues for 28 days, and continue monitoring participants’ health for approximately 6 months. They will also measure how well the body’s immune system responds to the vaccines by checking blood samples and documenting any cases of flu-like illness that occur during the study period.

The purpose of this research is to understand how zanamivir works in the bodies of very young infants and newborns when given as a single dose and as multiple doses. The study will examine how the medicine moves through the body and check its safety in these young patients. All participants will receive the study medication – there is no placebo used in this study.

During the study, participants will receive the medication through an intravenous line for up to 10 days. The maximum daily dose will be 24 mg per kilogram of body weight. The healthcare team will monitor the patients and collect blood samples to measure how the medicine is processed by their bodies. This information will help determine the most appropriate dosing for young infants with severe flu infections.

Participants in the study will receive either aspirin or a placebo, which looks like the aspirin tablet but does not contain any active medication. The study will also involve another medication called pantoprazole, which is used to protect the stomach lining. The treatment period will last for up to 90 days, and the researchers will monitor the participants’ health for any heart-related events and other outcomes over a period of 180 days.

The goal of this study is to determine if aspirin can provide additional benefits in preventing heart-related complications in patients with pneumonia. By understanding the potential benefits of aspirin in this context, the study hopes to improve treatment strategies for patients with pneumonia who are at risk of heart problems. Participants will be closely monitored throughout the study to ensure their safety and well-being.

The purpose of the study is to understand how well Baloxavir Marboxil works in treating the flu in children and to observe any changes in the flu virus that might occur during treatment. The study will monitor children who have been diagnosed with the flu and will involve taking samples at different times to check for any changes in the virus. These samples will help researchers see if the virus becomes resistant to the medication.

Participants in the study will receive the medication and will be observed over a short period. The study will involve several visits where samples will be collected to monitor the virus and any side effects of the medication. The goal is to gather information on how the flu virus responds to Baloxavir Marboxil and to ensure the safety and effectiveness of the treatment in children.